Article By:
Bio Deep Dives
Wednesday, May 3, 2023 9:50 AM EDT
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?